Skip to main content
Explore URMC

Acute Myeloid Leukemia (AML): Uproleselan Administered With Chemotherapy Versus Chemotherapy Alone in Patients With Relapsed/Refractory AML

Research Question:
Does the drug Uproleselan help the survival of patients with acute myeloid leukemia?

Basic Study Information

The purpose of this trial is to compare overall survival achieved with uproleselan administered with chemotherapy versus chemotherapy alone.

Study Reference #: ILEU18074

Lead Researcher (Principal Investigator)

Lead Researcher: Jane Liesveld, MD

Study Contact Information

Study Coordinator: Haley Misch
Phone: (585) 275-9485

Additional Study Details

Contact This Study

This field is required
This field is required
You must agree to be contacted to continue.

Return to Search